Challenges and prospects in HER2-positive breast cancer-targeted therapy
Xi‐Yin Li, Xueying Zhang, Saige Yin, Jianyun Nie
Abstract
Breast cancer remains the most prevalent malignancy among women globally and ranks as the leading cause of cancer-related mortality in this demographic. Approximately 13 %–15 % of all breast cancer cases are classified as HER2-positive, a subtype associated with a particularly unfavorable prognosis. A large number of patients with HER2-positive breast cancer continue to face disease progression after receiving standardized treatment. Given these challenges, a thorough exploration into the mechanisms underlying drug resistance in HER2-targeted therapy is imperative. This review focuses on the factors related to drug resistance in HER2-targeted therapy, including tumor heterogeneity, antibody-binding efficacy, variations in the tumor microenvironment, and abnormalities in signal activation and transmission. Additionally, corresponding strategies to counteract these resistance mechanisms are discussed, to advance therapeutic efficacy and clinical benefits in the management of HER2-positive breast cancer. • After receiving standardized treatment, a lot of HER2-positive breast cancer patients continue to face disease progression. • It is imperative to explore the mechanisms underlying drug resistance in HER2-targeted therapy. • This review focuses on the factors related to drug resistance in HER2-targeted therapy. • This review also discussed the strategies to counteract these resistance mechanisms. • Aim to advance therapeutic efficacy and clinical benefits in the management of HER2-positive breast cancer.